GLI1 and cancer: In addition to resistance, issues related to drug administration,pharmacokinetics, and the heterogeneous mechanisms of Hh pathway activationacross cancer subtypes limit the clinical translation of existinginhibitors.12,13 Therefore, there is a need fornovel Hh inhibitors that are effective in cancers with constitutiveHh activation and Gli1 overexpression.